enzyme of the mevalonate‐independent pathway of the isoprenoid biosynthesis. Using fosmidomycin as a specific inhibitor of Dxr, this enzyme was previously validated as target for the treatment of malaria and bacterial infections. The replacement of the formyl residue of fosmidomycin by spaciousacylresidues yielded inhibitors active in the micromolar range. As predicted by flexible docking, evidence was